Enveric Biosciences, Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2026 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number 001-38286 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 245 First Street , Riverview II , 18th Floor Cambridge , MA 02142 (Address of principal executive offices) (Zip code) (617) 444-8400 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share ENVB The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of August 12, 2026, the Registrant had 4,475,884 shares of Common Stock (par value $ 0.01 per share) outstanding. ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES FORM 10-Q TABLE OF CONTENTS Page PART I - FINANCIAL INFORMATION Item 1. Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026 and 2025 3 Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three and six months ended June 30, 2026 and 2025 4 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3. Quantitative and Qualitative Disclosures About Market Risk 21 Item 4. Controls and Procedures 21 PART II - OTHER INFORMATION Item 1. Legal Proceedings 22 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 1 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash $ 8,296,296 $ 4,677,491 Prepaid expenses and other current assets 497,029 259,216 Total current assets 8,793,325 4,936,707 Other assets: Property and equipment, net 81,929 159,234 Deferred offering costs, non-current 68,745 — Total other assets 150,674 159,234 Total assets $ 8,943,999 $ 5,095,941 LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable $ 682,794 $ 581,020 Due to related parties 26,750 99,875 Accrued expenses and other current liabilities 151,931 237,505 Total current liabilities 861,475 918,400 Commitments and contingencies (Note 9) - - Mezzanine equity Series C redeemable preferred stock, $ 0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively — — Total mezzanine equity — — Shareholders’ equity Preferred stock, $ 0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $ 0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively — — Common Stock, $ 0.01 par value, 100,000,000 shares authorized, 3,935,884 and 1,061,533 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 39,358 10,615 Additional paid-in capital 128,145,545 119,593,456 Accumulated deficit ( 119,507,698 ) ( 114,846,492 ) Accumulated other comprehensive loss ( 594,681 ) ( 580,038 ) Total shareholders’ equity 8,082,524 4,177,541 Total liabilities, mezzanine equity, and shareholders’ equity $ 8,943,999 $ 5,095,941 See the accompanying notes to the unaudited condensed consolidated financial statements. 2 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 2026 2025 2026 2025 For the Three Months Ended June 30, For the Six Months Ended June 30, 2026 2025 2026 2025 Operating expenses General and administrative $ 1,635,478 $ 1,219,018 $ 2,885,439 $ 2,579,156 Research and development 1,355,137 1,260,051 1,701,106 2,006,422 Depreciation and amortization 36,826 39,980 74,066 121,004 Total operating expenses 3,027,441 2,519,049 4,660,611 4,706,582 Loss from operations ( 3,027,441 ) ( 2,519,049 ) ( 4,660,611 ) ( 4,706,582 ) Other (expense) income Other income — — — 2,565 Interest (expense) income, net ( 292 ) ( 132 ) ( 595 ) ( 130 ) Total other (expense) income ( 292 ) ( 132 ) ( 595 ) 2,435 Net loss before income taxes ( 3,027,733 ) ( 2,519,181 ) ( 4,661,206 ) ( 4,704,147 ) Income tax expense — — — — Net loss $ ( 3,027,733 ) $ ( 2,519,181 ) $ ( 4,661,206 ) $ ( 4,704,147 ) Other comprehensive loss Foreign currency translation ( 7,625 ) 24,473 ( 14,643 ) 20,986 Comprehensive loss $ ( 3,035,358 ) $ ( 2,494,708 ) $ ( 4,675,849 ) $ ( 4,683,161 ) Net loss per share - basic and diluted $ ( 0.76 ) $ ( 11.65 ) $ ( 1.70 ) $ ( 25.76 ) Weighted average shares outstanding, basic and diluted 3,987,084 216,311 2,743,993 182,590 See the accompanying notes to the unaudited condensed consolidated financial statements. 3 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY Shares Amount Capital Deficit Loss Equity FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Common Stock Additional Paid-In Accumulated Accumulated Other Comprehensive Total Shareholders’ Shares Amount Capital Deficit Loss Equity Balance at January 1, 2026 1,061,533 $ 10,615 $ 119,593,456 $ ( 114,846,492 ) $ ( 580,038 ) $ 4,177,541 Issuance of Common Stock and warrants in Private Placement, net of offering costs of $ 368,990 328,802 3,288 1,140,739 — — 1,144,027 Issuance of Common Stock for cash pursuant to ATM Agreement, net of offering costs of $ 54,484 497,200 4,972 1,286,066 — — 1,291,038 Stock based compensation — — 88,673 — — 88,673 Foreign exchange translation loss — — — — ( 7,018 ) ( 7,018 ) Net loss — — — ( 1,633,473 ) — ( 1,633,473 ) Balance at March 31, 2026 1,887,535 $ 18,875 $ 122,108,934 $ ( 116,479,965 ) $ ( 587,056 ) $ 5,060,788 Issuance of Common Stock and warrants in Private Placement, net of offering costs of $ 814,085 98,000 980 4,407,758 — — 4,408,738 Issuance of Common Stock and warrants in Private Placement, net of offering costs 98,000 980 4,407,758 — — 4,408,738 Exercise of warrants 1,950,349 19,503 1,503,739 — — 1,523,242 Stock based compensation — — 125,114 — — 125,114 Foreign exchange translation loss — — — — ( 7,625 ) ( 7,625 ) Net loss — — — ( 3,027,733 ) — ( 3,027,733 ) Balance at June 30, 2026 3,935,884 $ 39,358 $ 128,145,545 $ ( 119,507,698 ) $ ( 594,681 ) $ 8,082,524 FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 Common Stock Additional Paid-In Accumulated Accumulated Other Comprehensive Total Shareholders’ Shares Amount Capital Deficit Loss Equity Balance at January 1, 2025 56,501 $ 565 $ 108,261,264 $ ( 106,074,505 ) $ ( 594,517 ) $ 1,592,807 Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs of $ 755,487 102,444 1,024 4,243,443 — — 4,244,467 Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs 102,444 1,024 4,243,443 — — 4,244,467 Issuance of common shares for vested RSAs 1,215 12 ( 12 ) — — - Issuance of common shares for exercise of warrants 38,528 385 74,659 — — 75,044 Issuance of round up shares 7,283 73 ( 73 ) — — - Stock based compensation — — 193,848 — — 193,848 Foreign exchange translation loss — — — — ( 3,487 ) ( 3,487 ) Net loss — — — ( 2,184,966 ) — ( 2,184,966 ) Balance at March 31, 2025 205,971 $ 2,059 $ 112,773,129 $ ( 108,259,471 ) $ ( 598,004 ) $ 3,917,713 Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $ 179,714 46,197 462 555,042 — — 555,504 Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs 46,197 462 555,042 — — 555,504 Stock based compensation — — 206,260 — — 206,260 Foreign exchange translation gain — — — — 24,473 24,473 Net loss — — — ( 2,519,181 ) — ( 2,519,181 ) Balance at June 30, 2025 252,168 $ 2,521 $ 113,534,431 $ ( 110,778,652 ) $ ( 573,531 ) $ 2,184,769 See the accompanying notes to the unaudited condensed consolidated financial statements. 4 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 2026 2025 For the Six Months Ended June 30, 2026 2025 Cash Flows From Operating Activities: Net loss $ ( 4,661,206 ) $ ( 4,704,147 ) Adjustments to reconcile net loss to cash used in operating activities Change in fair value of warrant liability — ( 858 ) Change in fair value of investment option liability — ( 1,707 ) Loss on write-off of deferred offering costs 19,597 — Stock based compensation 213,787 400,108 Amortization of intangibles — 42,180 Depreciation expense 74,066 78,824 Change in operating assets and liabilities: Due to related parties ( 73,125 ) ( 133,016 ) Prepaid expenses and other current assets ( 276,132 ) 48,192 Accounts payable, accrued expenses and other current liabilities 1,635 ( 11,300 ) Net cash used in operating activities ( 4,701,378 ) ( 4,281,724 ) Cash Flows From Financing Activities: Proceeds from sale of Common Stock and warrants, net of offering costs 5,552,765 4,244,467 Proceeds from Common Stock sold for cash pursuant to the ATM Agreement, net of offering costs 1,291,038 578,499 Payment of deferred offering costs ( 18,838 ) — Proceeds from exercise of warrants 1,523,242 75,044 Net cash provided by financing activities 8,348,207 4,898,010 Effect of foreign exchange rate on changes on cash ( 28,024 ) ( 7,496 ) Net increase in cash 3,618,805 608,790 Cash at beginning of period 4,677,491 2,241,026 Cash at end of period $ 8,296,296 $ 2,849,816 Supplemental disclosure of cash flow transactions: Cash paid for interest $ — $ — Income taxes paid $ — $ — Non-cash financing and investing activities: Non-cash issuance of round-up shares $ — $ 874 Non-cash issuance of RSA vested shares $ — $ 146 Issuance of Placement Agent Warrants as offering costs $ 286,000 $ — Deferred offering costs not paid $ 26,257 $ — Offering costs accrued not paid $ — $ 22,995 See the accompanying notes to the unaudited condensed consolidated financial statements. 5 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1. BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES Nature of Operations Enveric Biosciences, Inc. (“Enveric” or the “Company”) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. The head office of the Company is located in Cambridge, Massachusetts. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Unlimited Liability Company, 1236567 B.C. Unlimited Liability Company, MagicMed USA, Inc. (“MagicMed”), Enveric Biosciences Canada Inc., Akos Biosciences, Inc. (“Akos”), and Enveric Therapeutics, Pty. Ltd. (“Enveric Therapeutics”). Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Previously, Enveric was developing the EVM201 Series, and its lead drug candidate EB-002 (formerly EB-373), for the treatment of neuropsychiatric disorders. The EVM201 series comprised next generation synthetic prodrugs of the active metabolite, psilocin. In the fourth quarter of 2024, Enveric out-licensed the EVM201 Series program to MycoMedica Life Sciences, who will seek to develop, manufacture, and commercialize EB-002, in exchange for certain development and milestone payments to Enveric. The Company unveiled an EVM401 Series on February 25, 2025, which is intended to broaden its pipeline with additional non-hallucinogenic molecules and strengthen the Company’s ability to target addiction and neuropsychiatric disorders for patients with limited options. While the Company intends to pursue development of the EVM401 Series, its primary focus is to develop its lead asset EB-003 in the EVM301 Series. The Company has advanced EB-003 into formal preclinical development studies in support of a future Investigational New Drug (“IND”) filing. Reverse Stock Split The Company effected a 1-for-12 reverse stock split (“Reverse Stock Split”) on October 23, 2025, which began trading on a split-adjusted basis on October 28, 2025, pursuant to which every 12 shares of the Company’s issued and outstanding Common Stock were reclassified as one share of Common Stock. The Reverse Stock Split had no impact on the par value of the Company’s Common Stock or the authorized number of shares of Common Stock. Unless otherwise indicated, all share and per share information prior to the Reverse Stock Split date of October 28, 2025 in these unaudited condensed consolidated financial statements are retroactively adjusted to reflect the Reverse Stock Split, prior to the rounding of any fractional shares. Any fractional share resulting from the Reverse Stock Split were rounded up to the next whole number of shares, upon which 78,682 roundup shares were issued in November 2025. Going Concern, Liquidity and Other Uncertainties The Company has incurred losses since inception resulting in an accumulated deficit of $ 119,507,698 as of June 30, 2026 and further losses are anticipated in the development of its business. Further, the Company has operating cash outflows of $ 4,701,378 for the six months ended June 30, 2026. For the six months ended June 30, 2026, the Company had a loss from operations of $ 4,660,611 . Since inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements. In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At June 30, 2026, the Company had cash of $ 8,296,296 and working capital of $ 7,931,850 . Cash increased to $ 8,296,296 at June 30, 2026 from $ 4,908,769 at March 31, 2026, an increase of $ 3,387,527 , or 69%, primarily as a result of proceeds received from the April 2026 private placement and warrant exercises, partially offset by cash used in operating activities. Management expects existing cash resources to fund operations only for a limited period and anticipates the need for additional capital to continue development activities and satisfy ongoing obligations. As a result, the Company’s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the unaudited condensed consolidated financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 6 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management’s opinion is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025, and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026. The Company’s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company’s consolidated financial statements for the year ended December 31, 2025. There were no significant changes to these accounting policies during the three and six months ended June 30, 2026. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock, the valuation of warrants, and accruals associated with third party providers supporting research and development efforts. Actual results could differ from those estimates. Foreign Currency Translation From inception through June 30, 2026, the reporting currency of the Company was the United States dollar while the functional currency of certain of the Company’s subsidiaries was the Canadian dollar or the Australian dollar. For the reporting periods ended June 30, 2026 and 2025, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result, the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United States dollar. The Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included in the unaudited condensed consolidated statements of shareholders’ equity as a component of accumulated other comprehensive loss. The Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations in the future. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred. 7 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the federal depository insurance coverage of $ 250,000 in the United States, AUD$ 250,000 in Australia and C$ 100,000 in Canada. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such accounts. As of June 30, 2026 and December 31, 2025, the Company had greater than $ 250,000 at United States financial institutions, less than AUD$ 250,000 in an Australian financial institution, and less than C$ 100,000 at a Canadian financial institution. Research and Development Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As actual costs become known, the Company adjusts its accruals accordingly. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. The Company uses the two-class method to determine earnings per share only when the Company is in an income position. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method). The computation of basic net loss per share for the three and six months ended June 30, 2026 and 2025 excludes potentially dilutive securities. The computations of net loss per share for each period presented are the same for both basic and fully diluted. In accordance with ASC 260, 7,052 and 466 RSUs that were fully vested as of June 30, 2026 and 2025, respectively, were included in basic and dilutive earnings per share as there were no remaining contingencies for these shares to be issued as of June 30, 2026 and 2025 and 540,000 pre-funded warrants are also included in basic and dilutive earnings per share as of June 30, 2026, as there is a nominal exercise price of $ 0.0001 . Subsequent to June 30, 2026, these pre-funded warrants were exercised - see Note 10. Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2026 and 2025 because the effect of their inclusion would have been anti-dilutive. SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES 2026 2025 For the three and six months ended June 30, 2026 2025 Warrants to purchase shares of Common Stock 5,876,233 289,701 Restricted stock units - vested and unissued 383 258 Restricted stock units - unvested 526,186 22,959 Investment options to purchase shares of Common Stock 389 389 Options to purchase shares of Common Stock 40 128 Total potentially dilutive securities 6,403,231 313,435 Segment Reporting The Company operates as one operating segment with a focus on developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The Company’s Chief Executive Officer (“CEO”) as the Chief Operating Decision Maker (“CODM”), manages and allocates resources to the operations of the Company on a consolidated basis. Consolidated loss from operations, which is reported in the accompanying unaudited condensed consolidated statements of operations, is the measure of segment profit or loss that is regularly reviewed by the CODM. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across research and development projects in line with the long-term company-wide strategic goals. Refer to the accompanying unaudited condensed consolidated statements of operations for the presentation of consolidated loss from operations for the three and six months ended June 30, 2026 and 2025. The measure of segment assets is reported in the accompanying unaudited condensed consolidated balance sheets as “Total assets.” There are no significant segment expenses as the expenses that are included in consolidated loss from operations are general and administrative and research and development. 8 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS As of June 30, 2026 and December 31, 2025, the prepaid expenses and other current assets of the Company consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS June 30, 2026 December 31, 2025 Prepaid insurance $ 241,455 $ 77,179 Prepaid other 111,879 88,607 Prepaid professional fees 63,000 — Deferred offering costs — 43,247 Prepaid product development 74,429 45,244 Prepaid value-added taxes 6,266 4,939 Total prepaid expenses and other current assets $ 497,029 $ 259,216 NOTE 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following assets which are located in Calgary, Canada, with all amounts translated into U.S. dollars: SCHEDULE OF PROPERTY AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION June 30, 2026 December 31, 2025 Lab equipment $ 778,765 $ 807,402 Computer equipment and leasehold improvements 26,413 27,384 Property and equipment, gross 26,413 27,384 Less: Accumulated depreciation ( 723,249 ) ( 675,552 ) Property and equipment, net of accumulated depreciation $ 81,929 $ 159,234 Depreciation expense was $ 36,826 and $ 39,980 for the three months ended June 30, 2026 and 2025, respectively and $ 74,066 and $ 78,824 for the six months ended June 30, 2026 and 2025, respectively. NOTE 5. ACCRUED LIABILITIES As of June 30, 2026 and December 31, 2025, the accrued liabilities of the Company consisted of the following: SCHEDULE OF ACCRUED LIABILITIES June 30, 2026 December 31, 2025 Professional fees $ 91,153 $ 130,247 Product development 31,986 12,681 Accrued franchise taxes 26,937 85,873 Other 1,855 8,704 Total accrued liabilities $ 151,931 $ 237,505 NOTE 6. RELATED PARTY TRANSACTIONS As of June 30, 2026 and December 31, 2025, the Company had current liabilities of $ 26,750 and $ 99,875 , respectively, due to related parties. This balance is related to payments due to board members of the Company. 9 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 7. SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS At the Market Offering The Company entered into an at the market offering agreement, or the (“ATM Agreement”), with H.C. Wainwright & Co., LLC, or (“Placement Agent”), acting as sales agent, on April 9, 2025, relating to shares of Common Stock. Under the ATM Agreement, the Company may offer and sell shares of Common Stock having an aggregate offering price of up to $ 1,854,151 from time to time through the Placement Agent. The Placement Agent will receive 3 % of the gross sales price of the shares sold as a placement fee. Because the purchase price per share to be paid for the shares of Common Stock that the Company may elect to sell under the ATM Agreement, if any, will fluctuate based on the market prices of the Company’s Common Stock at the time the Company elects to sell shares pursuant to the ATM Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that the Company will sell under the ATM Agreement, the purchase price per share the buyer will pay for shares purchased from the Company under the ATM Agreement, or the aggregate gross proceeds that the Company will receive from those purchases under the ATM Agreement. On February 6, 2026, the Company filed a prospectus supplement to increase the ATM Agreement’s capacity by an additional $ 1,346,000 under the Company’s existing shelf registration statement. On June 9, 2026, the Company filed an additional prospectus supplement to increase the ATM Agreement’s capacity by an additional $ 2,425,000 . Under this agreement, for the six months ended June 30, 2026, the Company issued 497,200 shares for net cash proceeds of $ 1,291,038 . As of June 30, 2026, $ 2,425,000 remains available to sell. Registered Direct Offering and Private Placement On January 27, 2026, the Company entered into a securities purchase agreement (the “January 2026 Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors in a registered direct offering, an aggregate of 328,802 shares of Common Stock, at a price of $ 4.41 per share (the “Registered Direct Offering”) for gross proceeds of approximately $ 1.5 million before the deduction of placement agent fees and offering expenses. The closing of the Registered Direct Offering occurred on January 28, 2026. In a concurrent private placement (the “Private Placement” and, together with the Registered Direct Offering, the “Offerings”), pursuant to the terms of the Purchase Agreement, the Company also agreed to issue and sell unregistered Series G warrants to purchase up to 328,802 shares of Common Stock (the “Series G Warrants”), and unregistered Series H warrants to purchase up to 328,802 shares of Common Stock (the “Series H Warrants”, and collectively with the Series G Warrants, the “Common Warrants”). The Common Warrants have an exercise price of $ 4.16 per share and are exercisable immediately. The Series G Warrants will expire five years following the effective date of the Resale Registration Statement (defined below), and the Series H Warrants will expire 18 months following the effective date of the Resale Registration Statement. The Placement Agent acted as the exclusive placement agent in connection with the Offerings. The Company agreed to pay the Placement Agent a cash fee equal to 7.0 % of the aggregate gross proceed of the Offerings as well as a management fee equal to 1.0 % of the aggregate gross proceeds of the Offerings. The Company also agreed to pay the Placement Agent up to $ 35,000 for accountable expenses including the Placement Agent’s legal fees and expenses, and $ 10,000 for a clearing agent fee. The Company also issued warrants to purchase up to 23,016 shares of Common Stock to the Placement Agent. The placement agent warrants have the same terms as the Series G Warrants, except the placement agent warrants have an exercise price of $ 5.5125 per share ( 125 % of the offering price). The grant date fair value of these placement agent warrants was estimated to be $ 63,000 on January 28, 2026 and was charged to additional paid-in capital as issuance costs. The fair value of the placement agent warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., (1) risk-free interest rate of 3.8 %; (2) expected life in years of 5.00 ; (3) expected stock volatility of 116.0 %; and (4) expected dividend yield of 0 %.). The Company also incurred legal and other offering-related fees of $ 305,990 , which were similarly charged to additional paid-in capital. 10 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On April 16, 2026, the Company entered into a securities purchase agreement (the “April 2026 Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “April Private Placement”) (i) 98,000 shares of the Company’s Common Stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,124,223 shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) Series I warrants to purchase up to 2,222,223 shares of Common Stock (the “Series I Warrants”), and (iv) Series J warrants to purchase up to 2,222,223 shares of Common Stock (the “Series J Warrants,” together with the Series I Warrants, the “April Common Warrants”). The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $ 0.0001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full. The April Common Warrants have an exercise price of $ 2.00 per share and are exercisable immediately. The Series I Warrants will expire five years following the effective date of the Resale Registration Statement, and the Series J Warrants will expire 18 months following the effective date of the Resale Registration Statement. The aggregate gross proceeds from the offering were approximately $ 5.0 million before deduction of placement agent fees and offering expenses. The closing of the private placement occurred on April 17, 2026. The Placement Agent acted as the exclusive placement agent in connection with the April Private Placement. The Company agreed to pay the Placement Agent a cash fee equal to 7.0 % of the aggregate gross proceed of the Offerings as well as a management fee equal to 1.0 % of the aggregate gross proceeds of the Offerings. The Company also issued warrants to purchase up to 155,556 shares of Common Stock to the Placement Agent. The placement agent warrants have the same terms as the Series I Warrants, except the placement agent warrants have an exercise price of $ 2.8125 per share ( 125 % of the offering price). The grant date fair value of these placement agent warrants was estimated to be $ 223,000 on April 17, 2026 and was charged to additional paid-in capital as issuance costs. The fair value of the placement agent warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., (1) risk-free interest rate of 3.9 %; (2) expected life in years of 5.12 ; (3) expected stock volatility of 116.0 %; and (4) expected dividend yield of 0 %.). The Company also incurred legal and other offering-related fees of $ 591,085 , which were similarly charged to additional paid-in capital. Exercise of Warrants During the three months ended June 30, 2026, 143,380 Series G Warrants were exercised for proceeds of $ 596,461 ; 222,746 Series H Warrants were exercised for proceeds of $ 926,623 and 1,584,223 Pre-Funded Warrants were exercised for proceeds of $ 158 . Stock Options 2020 Long-Term Incentive Plan, as amended (“Incentive Plan”) The Company’s stock based compensation expense, recorded within general and administrative expense in the unaudited condensed consolidated statement of operations and comprehensive loss, related to stock options for the three months ended June 30, 2026 and 2025 was $— and $ 414 , respectively. The Company’s stock based compensation expense, recorded within general and administrative expense, related to stock options for the six months ended June 30, 2026 and 2025 was $ 276 and $ 828 , respectively. There is no unrecognized stock-based compensation related to stock option expense as of June 30, 2026. Issuance of Restricted Stock Awards During the six months ended June 30, 2026 the Company issued 92,590 restricted stock awards with an aggregate fair value of $ 209,253 . The awards are all unvested as of June 30, 2026. For the three months ended June 30, 2026 and 2025, the Company recorded $ 17,438 and $ 0 , respectively, in stock-based compensation expense within general and administrative expense, related to restricted stock awards granted to Directors. For the six months ended June 30, 2026 and 2025, the Company recorded $ 17,438 and $ 0 , respectively, in stock-based compensation expense within general and administrative expense, related to restricted stock awards. As of June 30, 2026, there was $ 191,816 in unamortized stock-based compensation costs related to restricted stock awards which will be recognized over a weighted average period of 0.9 years. 11 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Issuance of Restricted Stock Units The Company’s activity in restricted stock units was as follows for the six months ended June 30, 2026: SCHEDULE OF RESTRICTED STOCK UNITS Number of shares Weighted average fair value Non-vested at January 1, 2026 122,615 $ 9.30 Granted 409,457 2.26 Forfeited — - Vested ( 5,886 ) 33.21 Non-vested at June 30, 2026 526,186 $ 3.90 For the three months ended June 30, 2026 and 2025, the Company recorded $ 107,676 and $ 205,846 , respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative and research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss. For the six months ended June 30, 2026 and 2025, the Company recorded $ 196,073 and $ 399,280 , respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative and research and development expenses in the condensed consolidated statement of operations and comprehensive loss. As of June 30, 2026, the Company had unamortized stock-based compensation costs related to restricted stock units of $ 1,741,914 which will be recognized over a weighted average period of 3.16 years. As of June 30, 2026, 7,435 restricted stock units are vested without shares of Common Stock being issued, with all of these shares due as of June 30, 2026. The following table summarizes the Company’s recognition of stock-based compensation for restricted stock units for the following periods: SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS 2026 2025 2026 2025 Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Stock-based compensation expense for RSUs: General and administrative $ 89,846 $ 102,434 $ 162,767 $ 195,060 Research and development 17,830 103,412 33,306 204,220 Total $ 107,676 $ 205,846 $ 196,073 $ 399,280 Warrants The following table summarizes information about shares issuable under warrants outstanding at June 30, 2026: SCHEDULE OF WARRANTS OUTSTANDING Warrant shares outstanding Weighted average exercise price Weighted average remaining life Outstanding at January 1, 2026 962,124 $ 37.81 3.2 Issued 7,404,845 1.65 — Exercised ( 1,950,349 ) 0.78 — Forfeited ( 387 ) 44,340.19 — Outstanding at June 30, 2026 6,416,233 $ 4.66 3.1 Exercisable at June 30, 2026 6,416,233 $ 4.66 3.1 12 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8. LICENSING AGREEMENTS On July 10, 2024, Akos entered into an Exclusive License Agreement (the “License Agreement”) with Aries Science and Technology, LLC, an Ohio limited liability company (“Aries”), pursuant to which Akos granted Aries a license of Akos’s patented radiation dermatitis topical product. Subsequent to the execution of the License Agreement, Aries transferred the licensed rights to its wholly owned subsidiary, Teotec Pharma. The license allows Aries, through Teotec Pharma, to use the patented formulation to develop pharmaceutical or non-pharmaceutical products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive (subject to certain exceptions contained in the License Agreement), worldwide, royalty-bearing, and includes the right to sublicense. Akos is entitled to potential license payments, milestone payments and royalties based on net revenues of the Licensed Product on a licensed product-by-licensed product and country-by-country basis pursuant to the terms of the Agreement. Aries has the option during the license term, to purchase the rights to each licensed product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable licensed product), fully paid, transferable right and license to the licensed product. The Company has not earned any revenue related to this agreement as of June 30, 2026. On November 7, 2024, the Company entered into an Out-Licensing Agreement (the “Agreement”) with MycoMedica Life Sciences, PBC, a Delaware public benefit corporation (“MycoMedica”), pursuant to which the Company will out-license EB-002 and its EVM201 series to MycoMedica for further development and sales of the product in treatment of neuropsychiatric disorders. MycoMedica will receive an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound. As part of the Agreement, the Company received a $ 20,000 upfront payment in the fourth quarter of 2024, and if certain conditions are met, will receive development and sales milestone payments of up to $ 62 million and tiered single-digit royalties based on future sales. MycoMedica has the option during the license term to buyout its milestone and royalty payment obligations at a predetermined amount depending upon the stage of product development and commercialization at the time of the buyout. Further, MycoMedica has the right to purchase the licensed patents at a nominal amount upon a change of control of the Company, although doing so does not relieve MycoMedica of any of its payment obligations. The Company has not earned any revenue related to this agreement as of June 30, 2026. On February 3, 2025, Akos entered into two licensing agreements with Restoration Biologics LLC (“Restoration Biologics”), a biotechnology company focused on the treatment of joint disease. The companies have executed two licenses for Akos’ cannabinoid-COX-2 conjugate compounds, for pharmaceutical and potential non-pharmaceutical applications. The Company has not earned any revenue related to these agreements as of June 30, 2026. NOTE 9. COMMITMENTS AND CONTINGENCIES The Company is periodically involved in legal proceedings, legal actions and claims arising in the ordinary course of business. Management believes that the outcome of such legal proceedings, legal actions and claims will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Other Consulting and Vendor Agreements The Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services, with terms ranging between one and 12 months. These agreements, in aggregate, commit the Company to approximately $ 2.3 million in future cash payments. NOTE 10. SUBSEQUENT EVENTS Subsequent to June 30, 2026, all 540,000 outstanding pre-funded warrants were exercised for a de minimis amount of proceeds, and the Company issued 540,000 shares of Common Stock in connection with the exercises. 13 Item 2. Management’s discussion and analysis of financial condition and results of operations The information set forth below should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless stated otherwise, references in this Quarterly Report on Form 10-Q to “us,” “we,” “our,” or our “Company” and similar terms refer to Enveric Biosciences, Inc., a Delaware corporation, and its subsidiaries Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “may,” “plans,” “seeks,” “projects,” “targets,” and “would” or the negative of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, but are not limited to, future financial and operating results, the company’s plans, objectives, expectations and intentions and other statements that are not historical facts. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from our historical experience and our present expectations. Specific forward-looking statements in this quarterly report include statements, among others, regarding: ● our belief that EB-003 is the first known compound to selectively engage both 5-HT 2A and 5-HT 1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience; ● our intention to broaden our pipeline with additional non-hallucinogenic molecules with the unveiling of the EVM401 Series; ● our belief that the EVM401 Series will strengthen our ability to target addiction and neuropsychiatric disorders for patients with limited options; ● our intention to pursue the EVM401 Series, but primarily focus on developing our lead asset EB-003 in the EVM301 Series; ● our belief that factors exist that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements; ● management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined cash spending; ● our belief that adequate additional financing may not be available to the Company on acceptable terms, or at all; ● our belief that should the Company be unable to raise sufficient additional capital, the Company may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities; ● our exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United States dollar; ● our belief that the outcome of such legal proceedings that the Company may periodically be engaged in the normal course of business will not have a significant adverse effect on the Company’s financial position, results of operations or cash flows; ● our ability to continue as a going concern; ● our belief that our lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient; ● the advancement of EB-003 through preclinical studies and aim of initiating the first-in-human studies to asses safety and tolerability including non-hallucinogenic properties, followed by clinical trial targeting the treatment of depression or other neuropsychiatric disorders; ● our intention to assemble a team of clinical experts and principal investigators with experience across multiple mental health and central nervous system indications to be responsible for the management, monitoring, and integrity of the clinical research; ● our plan to submit filings including Investigational New Drug (“IND”) applications and, eventually, new drug applications (NDAs) to seek approval with the U.S. Food and Drug Administration (FDA) and with responsible regulatory agencies in other jurisdictions, in connection with our product candidates; ● our intention to broaden the pipeline with non-hallucinogenic molecules and strengthen our ability to target addiction and neuropsychiatric disorders for patients with limited options through the unveiling of our EVM401 Series; ● our belief that our continued development of the Psybrary™ will help us identify and develop the right drug candidates needed to address mental health challenges, including depression, anxiety, and addiction disorders; and ● our success at managing the risks involved in the foregoing. 14 Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, our ability to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. For a more detailed discussion of these and other factors that may affect our business and that could cause the actual results to differ materially from those projected in these forward-looking statements, see the risk factors and uncertainties set forth in Part II, Item 1A of this Form 10-Q and Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2025. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise, except as required by law. Business Overview We are a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, we are advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Our lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. Our lead program, the EVM301 Series, and our lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient. EB-003 is a novel derivative of DMT. It is currently advancing through preclinical studies with the aim of initiating first-in-human studies to assess safety and tolerability including non-hallucinogenic properties, followed by clinical trials targeting the treatment of depression or other neuropsychiatric disorders. We intend to assemble a team of clinical experts and principal investigators with experience across multiple mental health and central nervous system indications to be responsible for the management, monitoring, and integrity of the clinical research. We plan to submit filings including IND applications and, eventually, NDAs to seek approval with the FDA and with responsible regulatory agencies in other jurisdictions, in connection with our product candidates. The selection, timing, duration, and design of any prospective studies are subject to regulatory filings, approval and finalization of commercial plans. Our EB-003 program has completed short-term dose-range finding toxicology studies and has advanced into IND-enabling, GLP compliant safety pharmacology, ADMET and longer-term toxicology studies. We unveiled the EVM401 Series on February 25, 2025, which is intended to broaden its pipeline with additional non-hallucinogenic molecules and strengthen our ability to target addiction and neuropsychiatric disorders for patients with limited options. While we intend to pursue development of the EVM401 Series, our primary focus is to develop our lead asset EB-003 in the EVM301 Series. 15 Neuroplastogens Following our amalgamation with MagicMed in September 2021, we have continued to pursue the development of MagicMed’s proprietary library, the Psybrary™, which we believe will help us to identify and develop the right drug candidates needed to address mental health challenges, including depression, anxiety, and addiction disorders. We synthesize novel phenylalkylamines and indolethylamines, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary™, which currently includes 20 patent families with claims covering a million potential molecular structures, over one thousand of which we have so far synthesized in sufficient quantities to identify and hundreds of which we have screened for receptor binding and other relevant activities. In order to build a pipeline of product candidates, we intend to both continue to internally develop new drug candidates with associated intellectual property and to acquire, through in-licensing, additional intellectual property from pharmaceutical and biotechnology companies and research institutions. The in-licensed assets could include both research stage and clinical stage drug candidates. During 2026, a post-grant review petition challenging one of our issued patents was withdrawn. We believe this development further supports the strength of our intellectual property portfolio and our strategy of developing and protecting novel neuroplastogenic compounds. While we intend to pursue development of the EVM401 Series, our primary focus is to develop our lead asset EB-003 in the EVM301 Series. During the second quarter of 2026, we continued to advance IND-enabling activities for EB-003. In May 2026, we reported positive results from preclinical phototoxicity analyses indicating no photoreactive potential for EB-003. In June 2026, we initiated GLP-compliant genotoxicity studies designed to evaluate the compound’s potential to interact with DNA and cause genetic mutations, which are among the studies required to support a future IND submission. We believe these activities represent important steps in advancing EB-003 toward planned first-in-human clinical studies. The development status of the product is shown in the table below: Product Candidates Targeted Indications Status Expected Next Steps EB-003 Mental health indication Preclinical Development IND Filing Psychedelic-inspired drug candidate Recent Developments ATM Agreement On June 9, 2026, the Company filed a prospectus supplement to increase the registered capacity of its ATM facility by an additional $2,425,000. By way of background, the Company previously entered into an at the market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, acting as sales agent (the “Sales Agent”), on April 9, 2025, relating to shares of Common Stock. Under the ATM Agreement, we may offer and sell shares of Common Stock from time to time through the Sales Agent. The Sales Agent receives 3% of the gross sales price of the shares sold as a placement fee. During the six months ended June 30, 2026, the Company issued 497,200 shares for net cash proceeds of $1,291,038. As of June 30, 2026, the Company has issued an aggregate of 607,442 shares under the ATM Agreement, reflecting issuances during both the prior year and the current year, for net cash proceeds of $2,927,837, and $2,425,000 remains available to sell. 16 April 2026 Private Placement On April 16, 2026, the Company entered into a securities purchase agreement (the “April 2026 Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “April Private Placement”) (i) 98,000 shares of the Company’s common stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,124,223 shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) Series I warrants to purchase up to 2,222,223 shares of Common Stock (the “Series I Warrants”), and (iv) Series J warrants to purchase up to 2,222,223 shares of Common Stock (the “Series J Warrants,” together with the Series I Warrants, the “April Common Warrants”). In connection with the April Private Placement, the Company entered into a Registration Rights Agreement pursuant to which it agreed to file a registration statement covering the resale of the shares and shares issuable upon exercise of the warrants issued in the April Private Placement (the “Resale Registration Statement”). The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full. The April Common Warrants have an exercise price of $2.00 per share and are exercisable immediately. The Series I Warrants expire five years following the effective date of the Resale Registration Statement, and the Series J Warrants expire 18 months following the effective date of the Resale Registration Statement. The aggregate gross proceeds from the April Private Placement were approximately $5.0 million before deducting Placement Agent fees and offering expenses. The closing of the private placement occurred on April 17, 2026. The Placement Agent acted as the exclusive placement agent in connection with the April Private Placement. The Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds of the April Private Placement and a management fee equal to 1.0% of the aggregate gross proceeds of the April Private Placement. The Company also issued warrants to purchase up to 155,556 shares of Common Stock to the Placement Agent. The Placement Agent warrants have substantially the same terms as the Series I Warrants, except the placement agent warrants have an exercise price of $2.8125 per share (125% of the offering price). Results of Operations The following table sets forth information comparing the components of net loss for the three months ended June 30, 2026 and 2025: For the Three Months Ended June 30, 2026 2025 Operating expenses General and administrative $ 1,635,478 $ 1,219,018 Research and development 1,355,137 1,260,051 Depreciation and amortization 36,826 39,980 Total operating expenses 3,027,441 2,519,049 Loss from operations (3,027,441 ) (2,519,049 ) Other expense Interest expense, net (292 ) (132 ) Total other expense (292 ) (132 ) Net loss before income taxes (3,027,733 ) (2,519,181 ) Income tax expense — — Net loss $ (3,027,733 ) $ (2,519,181 ) 17 General and Administrative Expenses Our general and administrative expenses increased to $1,635,478 for the three months ended June 30, 2026 from $1,219,018 for the three months ended June 30, 2025, an increase of $416,460, or 34%. This change was primarily driven by increases in salaries and wages of $430,894 and Delaware franchise tax fees of $50,000, offset by decreases in legal fees of $20,126 and investor relations of $52,798. Research and Development Expenses Our research and development expenses for the three months ended June 30, 2026 were $1,355,137 as compared to $1,260,051 for the three months ended June 30, 2025, for an increase of $95,086, or approximately 8%. This change was primarily driven by increases in salaries and wages of $108,820, and research costs of $52,307, offset by decreases in consulting fees of $65,365. Depreciation and Amortization Expense Depreciation and amortization expense for the three months ended June 30, 2026 was $36,826 as compared to $39,980 for the three months ended June 30, 2025, with a decrease of $3,154, or approximately 8%, due to full depreciation of certain fixed assets during 2026. The following table sets forth information comparing the components of net loss for the six months ended June 30, 2026 and 2025: For the Six Months Ended June 30, 2026 2025 Operating expenses General and administrative $ 2,885,439 $ 2,579,156 Research and development 1,701,106 2,006,422 Depreciation and amortization 74,066 121,004 Total operating expenses 4,660,611 4,706,582 Loss from operations (4,660,611 ) (4,706,582 ) Other (expense) income Other income — 2,565 Interest (expense) income, net (595 ) (130 ) Total other (expense) income (595 ) 2,435 Net loss before income taxes (4,661,206 ) (4,704,147 ) Income tax expense — — Net loss $ (4,661,206 ) $ (4,704,147 ) 18 General and Administrative Expenses Our general and administrative expenses increased to $2,885,439 for the six months ended June 30, 2026 from $2,579,156 for the six months ended June 30, 2025, an increase of $306,283, or 12%. This change was primarily driven by increases in salaries and wages of $418,996, offset by decreases in consulting fees of $32,051, investor relations of $74,149, and public company fees of $31,703. Research and Development Expenses Our research and development expense for the six months ended June 30, 2026 was $1,701,106 as compared to $2,006,422 for the six months ended June 30, 2025, a decrease of $305,316, or approximately 15%. This decrease was primarily driven by a decrease in consulting fees of $253,248 and, research costs of $38,335, offset by an increase in salaries and wages of $4,006. Depreciation and Amortization Expense Depreciation and amortization expense for the six months ended June 30, 2026 was $74,066 as compared to $121,004 for the six months ended June 30, 2025, for a decrease of $46,938, or approximately 39%, primarily related to full amortization of our intangible assets in the first quarter of 2025. Going Concern, Liquidity and Capital Resources The Company has incurred losses since inception resulting in an accumulated deficit of $119,507,698 as of June 30, 2026 and further losses are anticipated in the development of its business. For the six months ended June 30, 2026, the Company had a loss from operations of $4,660,611. Further, the Company had operating cash outflows of $4,701,378 for the six months ended June 30, 2026. Since inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of debt and equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements. In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At June 30, 2026, the Company had cash of $8,296,296 and working capital of $7,931,850. Cash increased to $8,296,296 at June 30, 2026 from $4,908,769 at March 31, 2026, an increase of $3,387,527, or 69%, primarily as a result of proceeds received from the April 2026 private placement and warrant exercises, partially offset by cash used in operating activities. Management expects existing cash resources to fund operations only for a limited period and anticipates the need for additional capital to continue development activities and satisfy ongoing obligations. As a result, the Company’s current cash on hand is insufficient to satisfy its operating cash needs for the 12 months following the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities. As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 19 Cash Flows Since inception, we have primarily used our available cash to fund our product development and operations expenditures. Cash Flows for the Six Months Ended June 30, 2026 and 2025 The following table sets forth a summary of cash flows for the years presented: For the Six Months Ended June 30, 2026 2025 Net cash used in operating activities $ (4,701,378 ) $ (4,281,724 ) Net cash provided by financing activities 8,348,207 4,898,010 Effect of foreign exchange rate on changes on cash (28,024 ) (7,496 ) Net increase in cash $ 3,618,805 $ 608,790 Operating Activities Net cash used in operating activities was $4,701,378 during the six months ended June 30, 2026, which consisted primarily of a net loss adjusted for non-cash items of $4,353,756, an increase in prepaid expenses and other current assets of $276,132, a decrease in related party payable of $73,125 and an increase in accounts payable and accrued liabilities of $1,635. Net cash used in operating activities was $4,281,724 during the six months ended June 30, 2025, which consisted primarily of a net loss adjusted for non-cash items of $4,185,600, a decrease in prepaid expenses and other current assets of $48,192, a decrease in due to related parties of $133,016, and a decrease in accounts payable and accrued liabilities of $11,300. Financing Activities Net cash provided by financing activities was $8,348,207 during the six months ended June 30, 2026, which consisted of $5,552,765 in net proceeds from the sale of Common Stock and warrants, $1,523,242 of proceeds from warrant exercises, and $1,291,038 in net proceeds from the sale of Common Stock pursuant to the ATM Agreement, offset slightly by $18,838 in payments of deferred offering costs. Net cash provided by financing activities was $4,898,010 during the six months ended June 30, 2025, which consisted of $4,244,467 in net proceeds from the sale of Common Stock, net of offering costs, $75,044 in proceeds from the exercise of warrants, and $578,499 in proceeds from Common Stock sold under the ATM Agreement, net of offering costs. Critical Accounting Estimates Our unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, costs and expenses and related disclosures. Our critical accounting estimates are those estimates that involve a significant level of uncertainty at the time the estimate was made, and changes in them have had or are reasonably likely to have a material effect on our financial condition or results of operations. Accordingly, actual results could differ materially from our estimates. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025. 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk Not applicable. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures designed to ensure that the information we are required to disclose in reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified under the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. As required by paragraph (b) of Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer (our principal executive) and Chief Financial Officer (our principal financial officer and principal accounting officer) carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2026. Based on this evaluation, and in light of the material weaknesses found in our internal controls over financial reporting as of December 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act) were not effective as of June 30, 2026. Management’s Remediation Plan As previously discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, management had concluded that our internal control over financial reporting was not effective as of December 31, 2025, because management identified material weaknesses related to limited personnel and resources, including inadequate segregation of duties to ensure the proper processing, review, and authorization of routine and non-routine transactions; insufficient oversight of work performed and a lack of effective compensating controls within the finance and accounting functions; and the failure to adequately document, formalize, implement, and test controls, policies, and procedures, including those related to the control environment, risk assessment, information technology, and monitoring, which, in the aggregate, amounted to a material weakness in the Company’s internal control over financial reporting. See Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2025 for further discussion of our remediation plan. Changes in Internal Control over Financial Reporting Other than the changes being undertaken as part of the Company’s remediation plan, there have been no other changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during quarter ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 21 PART II. OTHER INFORMATION Item 1. Legal proceedings We may periodically be involved in legal proceedings, legal actions and claims arising in the ordinary course of business. In the opinion of management, we do not have any pending litigation that, separately or in the aggregate, have a material adverse effect on our financial position, results of operations or cash flows. Item 1A. Risk factors Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 27, 2026, as well as the risks and uncertainties described in the Company’s subsequently filed Quarterly Reports on Form 10-Q and other filings with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, other than as described below, there have been no material changes to the risk factors disclosed in the Company’s Annual Report. Our ability to maintain compliance with Nasdaq listing standards may be adversely affected by Nasdaq’s recently approved Market Value of Listed Securities requirement, and any failure to satisfy applicable listing standards could result in the delisting of our Common Stock. In July 2026, the SEC approved a Nasdaq rule change establishing a new continued listing requirement based on a company’s market value of listed securities (“MVLS”). Under the new requirement, companies listed on the Nasdaq Capital Market generally must maintain an MVLS of at least $5 million. Although the implementation of this requirement is currently stayed, and our MVLS was above the $5 million threshold as of the date of this Quarterly Report, our MVLS has recently been near that threshold and there can be no assurance that we will continue to satisfy the requirement if and when it becomes operative. MVLS is calculated by multiplying the market price of our Common Stock by the number of our outstanding listed shares. The market price of our Common Stock may fluctuate significantly as a result of factors that are beyond our control, including market conditions, investor sentiment, developments relating to our business, clinical, regulatory or financing activities, dilution resulting from future issuances of securities, and broader economic and geopolitical conditions. If the new MVLS requirement becomes operative and our MVLS falls below $5 million and remains below that threshold for the applicable measurement period, Nasdaq could issue a Staff Delisting Determination. Under the approved rule, a hearing request generally would not stay the suspension of trading of our Common Stock. As a result, our Common Stock could be suspended from trading on Nasdaq and trade, if at all, on the over-the-counter market while any appeal is pending. Although we may have the ability to appeal a Staff Delisting Determination, the authority of the Nasdaq Hearings Panel to grant relief is limited and may require us to demonstrate compliance with Nasdaq’s initial listing standards, which are more stringent than Nasdaq’s continued listing standards and which we may be unable to satisfy. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information None. 22 Item 6. Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 4.2 Form of Series I Warrant (incorporated by reference to Exhibit 4.2 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 4.3 Form of Series J Warrant (incorporated by reference to Exhibit 4.3 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 4.4 Form of Placement Agent Warrants (incorporated by reference to Exhibit 4.4 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 10.1 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 10.2 Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of our company’s Current Report on Form 8-K, filed with the Commission on April 20, 2026) 10.3 Form of RSU Agreement (incorporated by reference to Exhibit 10.1 of our company’s Current Report on Form 8-K, filed with the Commission on May 29, 2026) 10.4 Form of RSA Agreement (incorporated by reference to Exhibit 10.2 of our company’s Current Report on Form 8-K, filed with the Commission on May 29, 2026) 10.5 Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-8, filed with the Commission on March 24, 2025) 31.1 Certification pursuant to Section 302 of the Sarbanes–Oxley Act of 2002 of Principal Executive Officer* 31.2 Certification pursuant to Section 302 of the Sarbanes–Oxley Act of 2002 of Principal Financial and Accounting Officer* 32 Certification pursuant to Section 906 of the Sarbanes–Oxley Act of 2002 of Principal Executive Officer, Principal Financial and Accounting Officer** 101.INS Inline XBRL Instance Document* 101.SCH Inline XBRL Taxonomy Extension Schema* 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document* 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document* 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document* 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** Furnished herewith. 23 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 14, 2026. Enveric Biosciences, Inc. By: /s/ Joseph Tucker Name: Joseph Tucker, Ph.D. Title: Chief Executive Officer (Principal Executive Officer) By: /s/ Kevin Coveney Name: Kevin Coveney Title: Chief Financial Officer (Principal Financial and Accounting Officer) 24